Opinion
Adopted on 12/12/2012
Reference:
INT/658-EESC-2012-2059Referral:
COM(2012) 369 final - 2012/0192 (COD)Rapporteur:
Plenary session:
485 -
Dec 12, 2012 Dec 13, 2012
Pharmaceuticals
Displaying 11 - 20 of 25
Pages
Opinion
Adopted on 12/07/2012
Reference:
INT/642-EESC-2012-1573Referral:
COM(2012) 84 final - 2012/0035 (COD)Rapporteur:
Plenary session:
482 -
Jul 11, 2012 Jul 12, 2012
Opinion
Adopted on 28/03/2012
Reference:
INT/637-EESC-2012-810Referral:
COM(2012) 49 final - 2008/0255 (COD)Plenary session:
479 -
Mar 28, 2012 Mar 29, 2012
Opinion
Adopted on 28/03/2012
Reference:
INT/636-EESC-2012-809Referral:
COM(2012) 48 final - 2008/0256 (COD)Plenary session:
479 -
Mar 28, 2012 Mar 29, 2012
Opinion
Adopted on 22/02/2012
Reference:
INT/602-EESC-2012-469Referral:
COM(2011) 633 final - 2008/0256 (COD)Plenary session:
478 -
Feb 22, 2012 Feb 23, 2012
Opinion
Adopted on 22/02/2012
Reference:
INT/601-EESC-2012-468Referral:
COM(2011) 632 final - 2008/0255 (COD)Plenary session:
478 -
Feb 22, 2012 Feb 23, 2012
Opinion
Adopted on 30/09/2009
Reference:
INT/478-EESC-2009-1456Referral:
COM(2008) 666 finalRapporteur:
Plenary session:
456 -
Sep 30, 2009 Oct 01, 2009